Status:

TERMINATED

The Benefits of a Preoperative Anemia Management Program

Lead Sponsor:

University of Alabama at Birmingham

Conditions:

Anemia, Iron-Deficiency

Eligibility:

All Genders

19-80 years

Phase:

NA

Brief Summary

The goal of this study is to gain further insight into the comparative effectiveness of treating patients, who are found to be anemic before their elective surgery, with a series of weekly subcutaneou...

Detailed Description

Patient blood management (PBM) involves the timely and conscientious use of the current best evidence in making medical and surgical decisions about the care of patients to maintain red blood cell lev...

Eligibility Criteria

Inclusion

  • 19 years to 80 years of age
  • American Society of Anesthesiologists 1-3 status
  • Undergoing total hip arthroplasty for osteoarthritis, (either a primary or replacement procedure, but not a revision procedure) OR avascular necrosis (AVN); OR undergoing total knee arthroplasty (replacement) for osteoarthritis

Exclusion

  • American Society of Anesthesiologists 4 status
  • Severe anemia, defined as a hematocrit of \< 30%
  • History of hypercoagulability or thrombophilia (e.g, factor V Leiden)
  • History of deep venous thrombosis (DVT) or venous thromboembolism (VTE) within last 12 months
  • Current use of anticoagulants (e.g., heparin, warfarin, dabigatran, etc)
  • Diagnosis of chronic renal insufficiency requiring dialysis
  • Morbid obesity (BMI \> 40)
  • History of allergic reaction to intravenous iron
  • History of allergic reaction to an erythropoietic stimulating agent (ESA)
  • History of sickle cell disease
  • History of hemochromatosis
  • History of liver dysfunction or congestive heart failure
  • History of substance abuse disorder
  • History of major psychiatric disorder (e.g., major depression, bipolar disorder, axis II personality disorder, schizophrenia)
  • Uncontrolled hypertension (defined as a systolic pressure ≥ 160 mmHg and/or a diastolic pressure ≥ 110 mmHg)
  • History of uncontrolled cardiac arrhythmias, cerebrovascular accident (CVA), transient ischemic attack (TIA), acute coronary syndrome (ACS), or other arterial thrombosis. ACS includes unstable angina, Q wave myocardial infarction (QwMI), and non-Q wave myocardial infarction (NQMI) within 6 months
  • History of pure red cell aplasia (PRCA) after treatment with an ESA
  • History of seizure disorder
  • Any active/current cancer within the last 12 months (not including non-melanoma skin cancer)
  • Pregnancy or lactation
  • Non-native English speaker (because validated Spanish language versions of two of the patient questionnaires are not available)

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT01888003

Start Date

April 1 2013

End Date

January 1 2015

Last Update

May 28 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UAB Highlands Hospital

Birmingham, Alabama, United States, 35294